Synthetic Biologics (NASDAQ:SYN) is scheduled to issue its quarterly earnings data after the market closes on Thursday, November 8th. Analysts expect the company to announce earnings of ($1.32) per share for the quarter.
Synthetic Biologics (NASDAQ:SYN) last issued its quarterly earnings data on Wednesday, August 8th. The company reported ($1.05) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.40) by $0.35.
NASDAQ SYN opened at $0.87 on Wednesday. Synthetic Biologics has a 12-month low of $0.77 and a 12-month high of $26.60.
Synthetic Biologics Company Profile
Synthetic Biologics, Inc, a late-stage clinical company, develops therapeutics designed to preserve the microbiome to protect and restore the health of patients. Its lead product candidates are in Phase III development, such as SYN-004 that is designed to protect the gut microbiome from the effects of commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C.
Receive News & Ratings for Synthetic Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics and related companies with MarketBeat.com's FREE daily email newsletter.